BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Lifonebart (VHB937) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Lifonebart (VHB937)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07094516-700@assetmemo.bio
DTSTAMP:20261121T005451Z
DTSTART;VALUE=DATE:20280914
DTEND;VALUE=DATE:20280915
SUMMARY:Lifonebart (VHB937): Phase 2 readout est. (NCT07094516)
DESCRIPTION:Lifonebart (VHB937)\, phase 2\, Alzheimer's Disease.\nStudy: A 
 Clinical Trial to Learn About the Effects of VHB937 in People With Early A
 lzheimer's Disease\nEstimated primary completion: 14 September 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/lifonebart-vhb937#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07094516
URL:https://assetmemo.bio/drug/lifonebart-vhb937#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
